SCHEMBL3684622

SCHEMBL3684622

CCCCCc1ccc(S(=O)(=O)N(CCC)CCSc2ccc(OCC(=O)O)c(C)c2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 6/20 0.43
PTPN1 P18031 3/20 0.43
ALDH1A1 P00352 1/20 0.41
GAA P10253 1/20 0.41
PPARA Q07869 1/20 0.40
CA2 P00918 3/20 0.40
CA9 Q16790 3/20 0.40
CA1 P00915 2/20 0.40
CA12 O43570 2/20 0.40
PSEN1 P49768 1/20 0.40
PSEN2 P49810 1/20 0.40
APH1B Q8WW43 1/20 0.40
NCSTN Q92542 1/20 0.40
APH1A Q96BI3 1/20 0.40
PSENEN Q9NZ42 1/20 0.40
CA4 P22748 1/20 0.40
PTGDR2 Q9Y5Y4 2/20 0.40
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
SLC22A6 Q4U2R8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3688843 0.97 PPARD (0.44) PPARDPTPN1ALDH1A1GAAPPARA
SCHEMBL3683314 0.94 PPARD (0.45) PPARDPTPN1ALDH1A1GAAPPARA
SCHEMBL3686523 0.91 PTPN1 (0.45) PPARDPTPN1PPARACA2CA9
SCHEMBL3681848 0.89 KEAP1 (0.45) PPARDPTPN1PPARACA2CA9
SCHEMBL3679328 0.88 PTGDR2 (0.44) PPARDPTPN1PPARACA2CA9
SCHEMBL3691500 0.88 PPARD (0.49) PPARDPTPN1GAAPPARACA2
SCHEMBL3686795 0.88 PTPN1 (0.43) PPARDPTPN1PPARACA2CA9
SCHEMBL3691579 0.87 PPARD (0.42) PPARDPTPN1GAAPPARACA2
SCHEMBL3697015 0.87 PPARD (0.52) PPARDCA2CA9CA1CA12
SCHEMBL3689567 0.87 PPARD (0.52) PPARDPTPN1PPARACA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1597248-B1 SULFONAMIDE DERIVATIVES AS PPAR MODULATORS LILLY CO ELI (US) 2007-12-26 EP claimed
US-20060217433-A1 Sulfonamide derivatives as ppar modulators ELI LILLY AND COMPANY (US) 2006-09-28 US claimed
US-7655641-B2 Sulfonamide derivatives as PPAR modulators ELI LILLY AND COMPANY (US) 2010-02-02 US disclosed
US-7655641-B2 Sulfonamide derivatives as PPAR modulators ELI LILLY AND COMPANY (US) 2010-02-02 US disclosed
US-7655641-B2 Sulfonamide derivatives as PPAR modulators ELI LILLY AND COMPANY (US) 2010-02-02 US disclosed
EP-1597248-B1 SULFONAMIDE DERIVATIVES AS PPAR MODULATORS LILLY CO ELI (US) 2007-12-26 EP disclosed
EP-1597248-B1 SULFONAMIDE DERIVATIVES AS PPAR MODULATORS LILLY CO ELI (US) 2007-12-26 EP disclosed
US-20060217433-A1 Sulfonamide derivatives as ppar modulators ELI LILLY AND COMPANY (US) 2006-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217433-A1 Sulfonamide derivatives as ppar modulators PPARD, PPARA, PPARG PPARD 1/4885PTPN1 1603/4885ALDH1A1 1050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.